全國(guó)服務(wù)咨詢(xún)熱線(xiàn)：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡(jiǎn)要描述：6-Mercaptopurine monohydrate 6112-76-16-Mercaptopurine anhydrous is a Nucleoside Metabolic Inhibitor.
產(chǎn)品型號(hào)：abs47027942廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2026-01-08訪 問(wèn) 量：612產(chǎn)品分類(lèi)
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 6112-76-1 |
|---|---|---|---|
| 分子式 | C5H4N4S | 純度 | ＞98% |
| 分子量 | 170.19 | 貨號(hào) | abs47027942 |
| 規(guī)格 | 25mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | used, usually in combination with other | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
6-Mercaptopurine monohydrate 6112-76-1
| 產(chǎn)品描述 | |
| 描述 | 6-Mercaptopurine anhydrous is a Nucleoside Metabolic Inhibitor. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. |
| 純度 | ＞98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 6-巰基嘌呤水合物 |
| 外觀 | 黃色結(jié)晶性粉末 |
| 可溶性/溶解性 | DMSO : 32 mg/mL (188.03 mM; Need ultrasonic and warming) |
| 生物活性 | |
| 靶點(diǎn) | DNA synthesis,PRPP Amidotransferase |
| In vitro(體外研究) | 6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-Mercaptopurine hydrate treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions. |
| In vivo(體內(nèi)研究) | In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerCancer Metabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢(xún)
微信掃一掃
地址：上海市浦東新區(qū)新浩路58號(hào)申江科創(chuàng)園18棟
郵箱：
傳真：